Your browser doesn't support javascript.
loading
Novel application potential of cinaciguat in the treatment of mixed hyperlipidemia through targeting PTL/NPC1L1 and alleviating intestinal microbiota dysbiosis and metabolic disorders.
Jia, Ang; Jiang, Hongfei; Liu, Wenjing; Chen, Pengwei; Xu, Qi; Zhang, Renshuai; Sun, Jufeng.
  • Jia A; The First Affiliated Hospital of Jinzhou Medical University, Jinzhou 121000, China.
  • Jiang H; The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao 266071, China.
  • Liu W; The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao 266071, China.
  • Chen P; Hainan Key Laboratory for Research and Development of Natural Products from Li Folk Medicine, Institute of Tropical Bioscience and Biotechnology, Chinese Academy of Tropical Agricultural Sciences, Haikou 571101, China. Electronic address: chenpengwei@itbb.org.cn.
  • Xu Q; School of Pharmaceutical Sciences, Laboratory of Immunology for Environment and Health, Shandong Analysis and Test Center, Qilu University of Technology (Shandong Academy of Sciences), Jinan 250353, China. Electronic address: xuqi8270@sina.com.
  • Zhang R; The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao 266071, China. Electronic address: zhangrenshuai@qdu.edu.cn.
  • Sun J; The First Affiliated Hospital of Jinzhou Medical University, Jinzhou 121000, China. Electronic address: jzleo0810@126.com.
Pharmacol Res ; 194: 106854, 2023 08.
Article en En | MEDLINE | ID: mdl-37460003

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Microbioma Gastrointestinal / Hiperlipidemias / Lipidosis Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Año: 2023 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Microbioma Gastrointestinal / Hiperlipidemias / Lipidosis Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Año: 2023 Tipo del documento: Article